testosterone 5 alpha reductase

Summary

Top Publications

  1. ncbi The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    John D McConnell
    University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    N Engl J Med 349:2387-98. 2003
  2. ncbi The influence of finasteride on the development of prostate cancer
    Ian M Thompson
    University of Texas Health Science Center, San Antonio, USA
    N Engl J Med 349:215-24. 2003
  3. ncbi Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    Urology 60:434-41. 2002
  4. ncbi Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period
    Mark C Scholz
    Prostate Oncology Specialists, Marina del Rey, California, USA
    J Urol 175:1673-8. 2006
  5. ncbi Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer
    G L Andriole
    Division of Urologic Surgery, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110, USA
    J Urol 172:915-9. 2004
  6. ncbi Phytotherapy in the management of benign prostatic hyperplasia
    F C Lowe
    Department of Urology, St Luke s Roosevelt Hospital Center, New York, New York 10023, USA
    Urology 58:71-6; discussion 76-7. 2001
  7. ncbi The prevention of prostate cancer--the dilemma continues
    Peter T Scardino
    N Engl J Med 349:297-9. 2003
  8. ncbi Reduced adipose glucocorticoid reactivation and increased hepatic glucocorticoid clearance as an early adaptation to high-fat feeding in Wistar rats
    Amanda J Drake
    Endocrinology Unit, School of Molecular and Clinical Medicine, University of Edinburgh, Molecular Medicine Centre, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
    Endocrinology 146:913-9. 2005
  9. ncbi Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia
    G Bartsch
    Department of Urology, University of Innsbruck, Austria
    BJU Int 93:27-9. 2004
  10. ncbi Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial
    Roger S Kirby
    St George s Hospital, London, United Kingdom
    Urology 61:119-26. 2003

Research Grants

Detail Information

Publications243 found, 100 shown here

  1. ncbi The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    John D McConnell
    University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    N Engl J Med 349:2387-98. 2003
    ..The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown...
  2. ncbi The influence of finasteride on the development of prostate cancer
    Ian M Thompson
    University of Texas Health Science Center, San Antonio, USA
    N Engl J Med 349:215-24. 2003
    ..Finasteride, an inhibitor of 5alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer...
  3. ncbi Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    Urology 60:434-41. 2002
    ..To study the efficacy and safety of dutasteride, a dual inhibitor of the 5-alpha-reductase isoenzymes types I and II...
  4. ncbi Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period
    Mark C Scholz
    Prostate Oncology Specialists, Marina del Rey, California, USA
    J Urol 175:1673-8. 2006
    ..Men with prostate cancer treated intermittently with TIP benefit from improved quality of life when TOP with recovered testosterone is prolonged. We examined factors influencing the duration of TOP...
  5. ncbi Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer
    G L Andriole
    Division of Urologic Surgery, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110, USA
    J Urol 172:915-9. 2004
    ..In this short-term pilot study we examined the effect of the dual 5alphaR inhibitor dutasteride on markers of tumor regression...
  6. ncbi Phytotherapy in the management of benign prostatic hyperplasia
    F C Lowe
    Department of Urology, St Luke s Roosevelt Hospital Center, New York, New York 10023, USA
    Urology 58:71-6; discussion 76-7. 2001
    ..So each agent/product must be studied individually. Until more appropriately conducted trials are undertaken, the efficacy of phytotherapeutic agents will remain unproven...
  7. ncbi The prevention of prostate cancer--the dilemma continues
    Peter T Scardino
    N Engl J Med 349:297-9. 2003
  8. ncbi Reduced adipose glucocorticoid reactivation and increased hepatic glucocorticoid clearance as an early adaptation to high-fat feeding in Wistar rats
    Amanda J Drake
    Endocrinology Unit, School of Molecular and Clinical Medicine, University of Edinburgh, Molecular Medicine Centre, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
    Endocrinology 146:913-9. 2005
    ..Acute exposure to HF diet alters glucocorticoid metabolism, predicting lower hepatic and adipose intracellular glucocorticoid concentrations, which may be a key mechanism protecting against the metabolic complications of obesity...
  9. ncbi Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia
    G Bartsch
    Department of Urology, University of Innsbruck, Austria
    BJU Int 93:27-9. 2004
  10. ncbi Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial
    Roger S Kirby
    St George s Hospital, London, United Kingdom
    Urology 61:119-26. 2003
    ..To evaluate the efficacy and tolerability of the selective alpha(1)-adrenergic antagonist doxazosin and the 5-alpha-reductase inhibitor finasteride, alone and in combination, for the symptomatic treatment of benign prostatic hyperplasia...
  11. ncbi Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia
    Frans Debruyne
    426 Department of Urology, University Hospital Nijmegen, Geert Grooteplein 10, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Eur Urol 46:488-94; discussion 495. 2004
    ..This paper reports the pooled results of a 2-year open-label extension of the three randomised studies assessing the long-term efficacy and safety of dutasteride...
  12. ncbi Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial
    Gerald Andriole
    Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Urol 172:1314-7. 2004
    ..It represents a biologically plausible target for chemoprevention through the inhibition of 5alpha-reductase isoenzymes...
  13. ncbi Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia
    Claude Schulman
    Department of Urology, University Clinics of Brussels, Erasme Hospital, Brussels, Belgium
    BJU Int 97:73-9; discussion 79-80. 2006
    ..To examine the long-term (4-year) safety and tolerability of dutasteride in the treatment of symptomatic benign prostatic hyperplasia (BPH)...
  14. ncbi 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions
    T Suzuki
    Department of Pathology, Tohoku University School of Medicine, Tohoku University Hospital N A, T M, Sendai 980 8575, Japan
    J Clin Endocrinol Metab 86:2250-7. 2001
    ....
  15. ncbi Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver
    Jukka Westerbacka
    Department of Medicine, Division of Diabetes, University of Helsinki, 00029 Helsinki, Finland
    J Clin Endocrinol Metab 88:4924-31. 2003
    ....
  16. ncbi Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia
    Michael Marberger
    Department of Urology at the University of Vienna, Vienna, Austria
    Nat Clin Pract Urol 3:495-503. 2006
    ..This provides a mandate for their use in men with enlarged prostates (volume >or=30 ml), who are at increased risk of disease progression...
  17. ncbi Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy
    Al Baha Barqawi
    Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:872-6. 2003
    ..To evaluate the efficacy and tolerability of combined finasteride and low-dose flutamide for prostate-specific antigen (PSA)-only recurrence after definitive therapy and to determine the predictors of recurrence-free survival...
  18. ncbi The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review
    Long G Wang
    Mount Sinai School of Medicine, Division of Hematology and Medical Oncology, New York, NY 10029, USA
    Oncol Rep 11:1325-9. 2004
    ..Thus, passage to androgen independence may have been slowed or arrested...
  19. ncbi Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats
    T Zaccheo
    Laboratory of Experimental Endocrinology, Department of Oncology Research, Pharmacia and Upjohn, Nerviano, Italy
    Prostate 35:237-42. 1998
    ..We evaluated the preventive effect of turosteride when administered during the latency period in this prostatic tumor model...
  20. ncbi The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data
    Jaspreet S Sandhu
    Department of Urology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Curr Urol Rep 5:274-9. 2004
    ..Furthermore, long-term 5-alpha-reductase inhibitor monotherapy, although slow in onset, is a viable therapy for symptom relief in men with mild to moderate symptoms...
  21. ncbi The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia
    Edward D Kim
    Department of Surgery, Division of Urology, University of Tennessee Medical Center, 1928 Alcoa Highway, Knoxville, TN 37920, USA
    Curr Urol Rep 5:267-73. 2004
    ..This article highlights recent studies regarding the use of baseline clinical parameters on predicting BPH progression...
  22. ncbi The impact of participation in a study of medical treatment of lower urinary tract symptoms on the incidence of prostate surgery
    L M Eri
    Department of Urology, Aker Hospital, Oslo, Norway
    World J Urol 19:256-8. 2001
    ..001). Among the Norwegian participants in SCARP, prostate surgery was performed more frequently after completion of SCARP. Several possible explanations are discussed...
  23. ncbi Prevention of prostate cancer
    S E DePrimo
    Department of Urology, Stanford University School of Medicine, California 94305-5118, USA
    Hematol Oncol Clin North Am 15:445-57. 2001
    ..This article summarizes the current status and opportunities in prostate cancer prevention...
  24. pmc Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia
    Wenqing Gao
    Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, Ohio State University, Columbus, Ohio 43210, USA
    Endocrinology 145:5420-8. 2004
    ..S-1 simply worked as androgen receptor partial agonist, whereas finasteride inhibited prostatic 5alpha-reductase. These studies indicate that SARMs may demonstrate clinical utility as single agent or combination therapy for BPH...
  25. ncbi Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia
    Gerald Andriole
    Division of Urological Surgery, Washington University in St Louis, St Louis, Missouri 63110, USA
    J Urol 172:1399-403. 2004
    ..We reviewed the physiological and pathogenic role of dihydrotestosterone (DHT), evidence for the beneficial effects of decreasing DHT through 5alpha-reductase inhibition and the effects of altering the androgen balance with these agents...
  26. pmc Two for the price of one?
    Mike Wyllie
    Urodoc Ltd, Maryland Ridgeway Road, Herne, Kent CT6 7LN, UK
    Br J Pharmacol 144:1-2. 2005
  27. ncbi Clinical application of 5alpha-reductase inhibitors
    A Cilotti
    Department of Clinical Physiopathology, Endocrine Unit, University of Florence, Italy
    J Endocrinol Invest 24:199-203. 2001
    ..Similarly, the dual inhibitors seem indicated in attempting to prevent prostatic cancer. The pure 5alpha-reductase 1 inhibitors seem the ideal drugs for treatment of acne and hirsutism...
  28. ncbi Effect of finasteride on risk of prostate cancer: how little we really know
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Cell Biochem 91:478-82. 2004
    ..Confirmation of a spurious tumor grade "inflation" will make the conclusions of this study clearer and define the benefits of finasteride chemoprevention in a more favorable light...
  29. ncbi Enzymatic and binding activities of 5 alpha-reductase and androgen receptors in hamster prostate
    Marisa Cabeza
    Department of Biological Systems and Animal Production Metropolitan University Xochimilco, Mexico D F, Mexico
    Proc West Pharmacol Soc 46:128-31. 2003
  30. ncbi Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate
    Yasuhiro Shibata
    Department of Urology, Gunma University School of Medicine, Maebashi, Gunma, Japan
    Urology 62:942-6. 2003
    ..The effectiveness of antiandrogens on the control of hemorrhagic status in prostatic diseases has been previously reported...
  31. ncbi 5 alpha-reductase inhibitors: what's new?
    Charlotte L Foley
    Prostate Cancer Research Unit, Institute of Urology and Nephrology, University College London, 67 Riding House Street, London W1W 7EY, UK
    Curr Opin Urol 13:31-7. 2003
    ..Medical therapy is now the first-line treatment for most men with symptomatic benign prostatic hyperplasia. This review aims to highlight the recent contributions to our understanding of 5 alpha-reductase inhibitor usage...
  32. ncbi 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum
    Marisa Cabeza
    Department of Biological Systems, Metropolitan University Xochimilco, Mexico D F, Mexico
    Proc West Pharmacol Soc 45:164-5. 2002
    ..The results of this study show that both finasteride and PM-9 inhibit 5 alpha-reductase in a competitive manner...
  33. ncbi [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia]
    G Bartsch
    Urol Universitätsklinik, Frauen und Kopfklinik, Anichstrasse 35, 6020 Innsbruck Osterreich
    Urologe A 41:412-24. 2002
    ..However, the circulating and intraprostatic DHT could be further reduced by a more effective dual 5-alpha-reductase inhibitor, which would be efficacious in the treatment of benign prostate hyperplasia and other DHT-related disorders...
  34. ncbi Hormonal prevention of prostate cancer
    Otis W Brawley
    Professor of Medicine, Oncology and Epidemiology, The Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Urol Oncol 21:67-72. 2003
    ..A placebo controlled randomized trial using finasteride, an inhibitor of 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone, is ongoing. The endpoint of this trial is reduction of prostate cancer incidence...
  35. ncbi The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism
    E M Lakryc
    Department of Gynecology of the Federal University of Sao Paulo, Escola Paulista de Medicina, Sao Paulo, Brazil
    Gynecol Endocrinol 17:57-63. 2003
    ..In conclusion, our data suggest that finasteride may be effective for the treatment of the hirsute woman with idiopathic hirsutism or polycystic ovary syndrome...
  36. ncbi Effects of finasteride on vascular endothelial growth factor
    S Häggström
    Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Sweden
    Scand J Urol Nephrol 36:182-7. 2002
    ..The objective of this study was to explore the response to finasteride on the vasculature and the expression of vascular endothelial growth factor (VEGF), a potent regulatory factor of angiogenesis in human prostate tissue...
  37. ncbi Effect of finasteride on the ovulatory function of normal women
    I Lane Wong
    Fertil Steril 79:1455-7. 2003
  38. ncbi [Finasteride: 10 years of clinical use. Systematic review of the literature]
    J F Jimenez Cruz
    Servicio de Urologia, Hospital Universitario La Fe, Valencia
    Actas Urol Esp 27:202-15. 2003
    ..After ten years of clinical use of Finasteride in patients with BPH, we carried out a systematic review of the literature including the assessment of their quality and grading the level of evidence for clinical recommendations...
  39. ncbi Testosterone stimulates proliferation and inhibits interleukin-6 production of normal and hereditary gingival fibromatosis fibroblasts
    Ricardo D Coletta
    Department of Oral Pathology, University of Campinas Dental School, Caixa Postal 52, 13414 018 Piracicaba SP, Sao Paulo, Brazil
    Oral Microbiol Immunol 17:186-92. 2002
    ..These results show that testosterone coordinates the proliferation and production of IL-6 of normal and HGF fibroblasts...
  40. ncbi Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia
    G Bartsch
    Department of Urology, University of Innsbruck, Austria
    World J Urol 19:413-25. 2002
    ..A clinical evaluation of potent dual 5alpha-reductase inhibitors may help to define the relative roles of human type 1 and 2 5alpha-reductase in the pathophysiology of benign prostatic hyperplasia and other androgen-dependent diseases...
  41. ncbi Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells
    Yuan Shan Zhu
    Department of Medicine Endocrinology, Weill Medical College of Cornell University, New York, New York, USA
    J Androl 24:681-7. 2003
    ..These results suggest that both 5alpha-reductase isozymes are present and functionally important in prostatic tumor LNCaP cells and that DHT is a major mediator of androgen induction of PSA gene expression in these cells...
  42. ncbi Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia
    Claus G Roehrborn
    University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 62:894-9. 2003
    ..To examine the effect of finasteride on serum testosterone in men with benign prostatic hyperplasia (BPH)...
  43. ncbi Determination of concentrations of sex steroids in blood plasma and semen of male dogs treated with delmadinone acetate or finasteride
    K Lange
    Institute for Reproductive Medicine, School of Veterinary Medicine, , D-30559 Hannover, Germany
    J Reprod Fertil Suppl 57:83-91. 2001
    ..Delmadinone acetate and finasteride caused reversible suppression of the secretory activity of the prostate gland. The application of delmadinone acetate led to a temporary alteration of maturation of epididymal spermatozoa...
  44. ncbi 5alpha-reductase inhibitors: what role should they play?
    S A Kaplan
    Department of Urology, Columbia University, New York, New York, USA
    Urology 58:65-70; discussion 70. 2001
    ..Baseline parameters, such as prostate volume, prostate-specific antigen values, and whether to administer finasteride in combination with alpha blockers, are among the factors that will determine the appropriateness of such therapy...
  45. ncbi 5alpha-reductase activity in the prostate
    W D Steers
    Department of Urology, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA
    Urology 58:17-24; discussion 24. 2001
    ....
  46. ncbi Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia
    Franklin C Lowe
    Department of Urology, Saint Luke s Roosevelt Hospital Center, New York, NY 10019, USA
    Urology 61:791-6. 2003
    ..To summarize the 6-year clinical trial data with finasteride. Benign prostatic hyperplasia is a chronic and progressive disease and therefore assessment of long-term safety and efficacy is important...
  47. ncbi Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells
    Claudio Festuccia
    Prostate Biology Laboratory Department of Experimental Medicine, University of L Aquila Science and Technology School, Via Vetoio Coppito 2, 67100 L Aquila, Italy
    J Cancer Res Clin Oncol 131:243-54. 2005
    ....
  48. pmc Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?
    Wenqing Gao
    Department of Pharmaceutical Sciences, School of Pharmacy, University at Buffalo SUNY, Buffalo, NY 14260, USA
    Mol Interv 7:10-3. 2007
    ....
  49. pmc Medical treatment of benign prostatic hyperplasia
    Stephen S Connolly
    Mater Misericordiae Hospital, Dublin, Ireland
    Postgrad Med J 83:73-8. 2007
    ..Pharmaceutical preparations are commonly used for benign prostate hyperplasia. This article reviews the current understanding of the natural history of the condition and the literature regarding medical treatment...
  50. ncbi Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate
    I R Ravish
    Department of Urology, KLES Kidney Foundation, Belgaum, India
    Arch Androl 53:17-20. 2007
    ..Dutasteride with its inhibitory effects on type 1 and 2 5alpha-reductase, produces significantly better results than Finasteride...
  51. ncbi Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer
    K Suzuki
    Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Science, Asahimachi 1 757, Niigata 951 8510, Japan
    Prostate Cancer Prostatic Dis 10:301-6. 2007
    ..This is the first report confirming this mechanism experimentally and also suggest the use of combined therapies that target ARs and prevent the formation of DHT within prostate cancer cells to achieve optimal therapeutic efficacy...
  52. ncbi 5alpha-reductase inhibition for men with enlarged prostate
    Muta M Issa
    Department of Urology, Emory University School of Medicine AVAMC 112, Atlanta, Georgia 30033, USA
    J Am Acad Nurse Pract 19:398-407. 2007
    ..This article reviews the use of alpha-blockers and 5alpha-reductase inhibitors (5ARIs) in the management of LUTS and enlarged prostate...
  53. ncbi Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer
    T C Shao
    Department of Medicine, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas 77030, USA
    J Urol 178:1521-7. 2007
    ..We evaluated the effects of dutasteride for preventing or delaying prostate growth and neoplastic changes in a transgenic model of prostate cancer...
  54. ncbi [Benign prostatic hyperplasia: medical therapy]
    B Schlenker
    Klinik und Poliklinik fur Urologie, Klinikum Grosshadern, Ludwig Maximilians Universitat Munchen
    MMW Fortschr Med 149:29-31; quiz 32. 2007
    ..Plant extracts, alpha-blockers and 5-alpha reductase inhibitors represent the most common prescribed substances. Recent data suggest beneficial effects for the use of antimuscarinic agents and phosphodiesterase type 5 inhibitors...
  55. ncbi [Comparison of different drugs on the treatment of benign prostate hyperplasia]
    Ning chen Li
    Department of Urology, Peking University First Hospital, Institute of Urology, Beijing 100034, China
    Zhonghua Wai Ke Za Zhi 45:947-50. 2007
    ..To compare the differences of the efficacy and different therapeutic drugs on the treatment of benign prostatic hyperplasia (BPH) in order to ensure the optimal indication for different BPH patients...
  56. ncbi [Hormonal therapy for benign prostatic hyperplasia]
    Hideki Sakai
    Department of Urology, Nagasaki University School of Medicine
    Nihon Rinsho 60:358-61. 2002
  57. ncbi The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment
    M Hill
    Institute of Endocrinology, Charles University, Prague, Czech Republic
    Horm Metab Res 28:562-4. 1996
    ..The prostatic tissue from the patients treated with finasteride for 8 weeks showed a significant decrease not only in DHT but also in androstenedione and epiT, whereas the concentration of testosterone increased significantly...
  58. pmc The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer
    Donald J Tindall
    Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 179:1235-42. 2008
    ..Dihydrotestosterone, the primary prostatic androgen, is transformed from testosterone by types 1 and 2 5alpha-reductase and, thus, a potential therapeutic benefit could be achieved through the inhibition of 5alpha-reductase...
  59. ncbi 5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives
    Michael Naslund
    University of Maryland School of Medicine, Baltimore, MD, USA
    Am J Manag Care 14:S148-53. 2008
    ....
  60. ncbi Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men
    Muta M Issa
    Department of Urology, Emory University, 1670 Clairmont Rd, Decatur, GA 30033, USA
    Am J Manag Care 14:S160-6. 2008
    ..To evaluate the likelihood of alpha-adrenergic antagonist (alpha-blocker) discontinuation in combination with dutasteride or finasteride among patients aged > or =65 years with enlarged prostate...
  61. doi Preventing prostate cancer: new analyses put finasteride back on the map
    Brian Vastag
    J Natl Cancer Inst 100:1132-3. 2008
  62. ncbi Association between 5-alpha reductase inhibition and risk of hip fracture
    Steven J Jacobsen
    Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S Los Robles Ave, Second Floor, Pasadena, CA 91101, USA
    JAMA 300:1660-4. 2008
    ..Short-term studies show no effects of these agents on bone metabolism,but long-term data are not available...
  63. ncbi Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men
    C G Roehrborn
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
    Prostate Cancer Prostatic Dis 9:432-8. 2006
    ..Therefore, dutasteride demonstrated similar efficacy and safety profiles in African-Americans and Caucasians...
  64. ncbi Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers
    Yi Xu
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:4072-9. 2006
    ..Therefore, the levels of expression SRD5A1 and SRD5A2 and the antiprostatic cancer growth response to finasteride, a selective SRD5A2 inhibitor, versus the dual SRD5A1 and SRD5A2 inhibitor, dutasteride, were compared...
  65. ncbi The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002)
    Remigio Vela-Navarrete
    Department of Urology, Clinical Epidemiology Unit, Fundacion Jimenez Diaz, Universidad Autonoma, Madrid, Spain
    BJU Int 96:1045-8. 2005
    ....
  66. ncbi Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride
    D Kinniburgh
    Contraceptive Development Network, Centre for Reproductive Biology, University of Edinburgh, United Kingdom
    J Androl 22:88-95. 2001
    ..However, these data do not support the involvement of 5alpha-reductase in maintaining residual spermatogenesis during gonadotropin suppression for hormonal male contraception...
  67. ncbi In vivo evidence for an increase in 5alpha-reductase activity in the rat central nervous system following morphine exposure
    Hossein Amini
    Department of Pharmacology, Neuroscience Research Center, Shaheed Beheshti University of Medical Sciences, P O Box 19835 355, Tehran, Iran
    Int J Dev Neurosci 23:621-6. 2005
    ..These results suggest that morphine exposure increase the CNS activity of 5alpha-reductase, which is an important metabolizing enzyme for testosterone...
  68. ncbi [5alpha-dihydrotestosterone (DHT)]
    Akira Komiya
    Department of Urology, Chiba University Hospital
    Nihon Rinsho 63:452-6. 2005
  69. ncbi Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia
    Ajay Nehra
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 96:237-43. 2005
    ..Finally, the capacity to be creative in academic departments is extolled as a core property of academicians, and its surfacing described as having the potential to revitalize individuals and departments...
  70. ncbi Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men
    John K Amory
    University of Washington, Box 356429, 1959 NE Pacific St, Seattle, WA 98195, USA
    J Androl 27:72-8. 2006
    ..Additional studies of the combination of oral T in oil with 5alpha-reductase inhibitors as a novel form of oral T therapy are warranted...
  71. ncbi Actions of 5alpha-reductase inhibitors on the epididymis
    Bernard Robaire
    Departments of Pharmacology and Therapeutics and of Obstetrics and Gynecology, McGill University, Montreal, Que, Canada
    Mol Cell Endocrinol 250:190-5. 2006
    ..Mating females to treated males resulted in fewer successful pregnancies and a higher rate of pre-implantation loss. Thus, there may be a role for dual 5alpha-reductase inhibitors as potential components of a male contraceptive...
  72. ncbi [Is tumour grade applicable to finasteride-treated prostate cancer?]
    Vincent Molinie
    Fondation Hopital Saint Joseph, Paris, France
    Prog Urol 15:387-91. 2005
    ....
  73. ncbi In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors
    Eugene Bratoeff
    Department of Pharmacy, Faculty of Chemistry, National University of Mexico City, Mexico D F, Mexico
    J Steroid Biochem Mol Biol 111:275-81. 2008
    ..Apparently the presence of the halogen atoms in compounds 11a-11c enhances the inhibitory activity for the 5alpha-reductase enzyme...
  74. ncbi Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration
    H K Ryu
    Bioanalysis and Biotransformation Research Centre, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul, 130 605, Korea
    Br J Dermatol 154:730-4. 2006
    ..It is also notable that the androgenic effect in MPB is different for each region of the head...
  75. ncbi Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men
    Steven A Kaplan
    Diabetes Care 29:749; author reply 749-50. 2006
  76. ncbi RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer
    W Reid Pitts
    J Urol 173:1433-4; author reply 1434-5. 2005
  77. ncbi Prostate cancer chemoprevention: Strategies for designing efficient clinical trials
    R Lieberman
    National Cancer Institute, Rockville, Maryland 20852, USA
    Urology 57:224-9. 2001
    ....
  78. pmc Gene expression in hair follicle dermal papilla cells after treatment with stanozolol
    M Reiter
    Physiology Weihenstephan Technische Universität München Weihenstephaner Berg 3, D 85354 Freising Germany
    Biomark Insights 4:1-8. 2008
    ..In this feasibility study first biomarker for a screening pattern of anabolic agents could be identified providing the rationality to investigate modified, metabolic pathways in the whole hair follicle...
  79. ncbi Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study
    Li Chen
    Key Laboratory of Drug Targeting and Novel Drug Delivery Systems, West China School of Pharmacy, Sichuan University, Chengdu, China
    Clin Ther 31:2242-8. 2009
    ..Information regarding its pharmacokinetics and bioequivalence was required to assess the efficacy and safety of this formulation before marketing it in China...
  80. ncbi In vitro modulation of steroid 5alpha-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia
    H Weisser
    Institute of Clinical Chemistry, Transfusion and Laboratory Medicine, University Clinic Bergmannsheil, Burkle de la Camp Platz 1, D 44789, Bochum, Germany
    Steroids 66:521-8. 2001
    ..Thus, changes in membrane phospholipid content seem to be instrumental in the expression of DHT-dependent processes...
  81. ncbi Undervirilization in XY newborns may hide a 5α-reductase deficiency: report of three new SRD5A2 gene mutations
    L Maimoun
    Service d Hormonologie, Hopital Lapeyronie, CHU Montpellier et UMI, Montpellier, France
    Int J Androl 33:841-7. 2010
    ..Early molecular diagnosis is indispensable for the crucial decision of the newborn's sex of rearing...
  82. ncbi The identification of 5 alpha-reductase-2 and 17 beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred
    S Can
    Department of Medicine, Cornell University Medical College, New York, New York 10021, USA
    J Clin Endocrinol Metab 83:560-9. 1998
    ....
  83. ncbi A class of 4-aza-lithocholic acid-derived haptens for the generation of catalytic antibodies with steroid synthase capabilities
    J Hasserodt
    Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA
    Bioorg Med Chem 8:995-1003. 2000
    ..Surprisingly, an inhibition study showed that the isomer with the inverted configuration at the N-oxide bound more strongly to this catalytic antibody...
  84. ncbi Occurrence of steroidogenic enzymes in the bovine mammary gland at different functional stages
    P Belvedere
    Department of Biology, University of Padova, Italy
    J Steroid Biochem Mol Biol 59:339-47. 1996
    ..It is uncertain, however, whether this conclusion applies to anestrous or ovariectomized lactating cows as well...
  85. ncbi In vitro inhibition of androstenedione 5alpha-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia
    H Weisser
    Institute of Clinical Chemistry, Transfusion and Laboratory Medicine, University Clinic Bergmannsheil, Bochum, Germany
    J Steroid Biochem Mol Biol 67:49-55. 1998
    ....
  86. pmc Isolated micropenis reveals partial androgen insensitivity syndrome confirmed by molecular analysis
    Amrit Bhangoo
    Pediatric Endocrinology Division of Maimonides Infants and Children s Hospital of Brooklyn, Children s Hospital at SUNY Downstate, Brooklyn, NY 11219, USA
    Asian J Androl 12:561-6. 2010
    ..This underlines the importance of including AR gene analysis in the evaluation of isolated micropenis with normal plasma T to ensure proper management of the patient and appropriate genetic counseling for the family...
  87. ncbi 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2
    A Guarna
    Dipartimento di Chimica Organica Ugo Schiff, Universita di Firenze, Italy
    J Med Chem 40:1112-29. 1997
    ..The results of ab initio calculations suggest that the inhibition potency of 19-nor-10-azasteroids could be directly related to the nucleophilicity of the carbonyl group in the 3-position...
  88. ncbi Pretranslational up-regulation of the hepatic microsomal delta4-3-oxosteroid 5alpha-oxidoreductase in male rat liver by all-trans-retinoic acid
    M Murray
    School of Physiology and Pharmacology, University of New South Wales, Sydney, Australia
    Biochem Pharmacol 58:355-62. 1999
    ....
  89. ncbi Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia
    Seog Jun Ha
    Department of Dermatology, St Paul s Hospital, The Catholic University of Korea, 620 56 Junnong 2 dong, Dongdaemun ku, 130 709, Seoul, South Korea
    J Dermatol Sci 31:135-41. 2003
    ..Genetic polymorphisms and ethnic variations have not been studied for Asians, although it is suggested that racial difference could exist and influence clinical phenotypes...
  90. ncbi Identification of missense mutations in the SRD5A2 gene from patients with steroid 5alpha-reductase 2 deficiency
    F Vilchis
    Department of Reproductive Biology, Instituto Nacional de la Nutricion Salvador Zubiran, Tlalpan, Mexico
    Clin Endocrinol (Oxf) 52:383-7. 2000
    ..Here we performed genomic DNA analyses from individuals bearing the enzyme deficiency in order to detect the molecular abnormalities...
  91. ncbi Changes in the expression of steroid metabolism-related genes in rat adrenal glands during selective REM sleep deprivation
    Kyoji Morita
    Neuroscience Group in Department of Pharmacology, Tokushima University School of Medicine, 3 18 15 Kuramoto, Japan
    Life Sci 72:1973-82. 2003
    ..These results indicate that REM sleep deprivation by itself may affect the expression of steroid metabolism-related genes in the adrenal gland, suggesting a possible relation between REM sleep and adrenocortical steroid metabolism...
  92. pmc Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5 alpha-reductase type 2 gene (SRD5A2)
    R Anwar
    Department of Medicine, University of Leeds
    Mol Pathol 50:51-2. 1997
    ..This mutation produces an amino acid change from glutamic acid to lysine, and may affect the ability of the enzyme to bind its co-factor...
  93. ncbi Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats
    N Yasuda
    Discovery Research Laboratories, Ono Pharmaceutical Co, Ltd, Osaka, Japan
    Jpn J Pharmacol 74:243-52. 1997
    ..These results suggest that ONO-9302 reduces the prostatic growth by inhibiting the conversion of T to DHT in the prostate without lowering blood T level unlike anti-androgen drugs...
  94. ncbi Steroid 5alpha-reductase inhibitors
    Eugenio Flores
    National University Mexico D F and Metropolitan University Mexico D F, Mexico
    Mini Rev Med Chem 3:225-37. 2003
    ..The trienones having a more coplanar structure react faster with the enzyme and thus show a higher inhibitory activity...
  95. ncbi Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer
    Najib Lamharzi
    Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Int J Cancer 105:480-3. 2003
    ....
  96. ncbi Uniparental disomy in steroid 5alpha-reductase 2 deficiency
    B Chavez
    Department of Reproductive Biology, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico
    J Clin Endocrinol Metab 85:3147-50. 2000
    ..The results of our study give evidence of the first case of 5alpha-reductase deficiency resulting from uniparental disomy and also disclose an alternate mechanism whereby this enzymatic disorder can derive from a single parent...
  97. ncbi Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways
    A G Latil
    Center for Research into Prostate Pathologies, Evry, France
    Cancer 92:1130-7. 2001
    ..The authors evaluated the association between polymorphisms in genes involved in the androgen biosynthesis and metabolism pathway and the risk of prostate carcinoma...
  98. ncbi Analysis of the steroid binding domain of rat steroid 5alpha-reductase (isozyme-1): the steroid D-ring binding domain of 5alpha-reductase
    A K Bhattacharyya
    VA Medical Center and Department of OB GYN, University of Kentucky, Lexington 40536, USA
    Steroids 64:197-204. 1999
    ..Site-directed mutagenesis studies indicated that mutant F18L showed an approximately 12-fold increase in the Km for testosterone, whereas the Km for reduced nicotinomide adenine dinucleotide phosphate remained virtually unaltered...
  99. pmc Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth
    R Bruce Montgomery
    Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
    Cancer Res 68:4447-54. 2008
    ..Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment...
  100. ncbi Expression cloning and characterization of oxidative 17beta- and 3alpha-hydroxysteroid dehydrogenases from rat and human prostate
    M G Biswas
    Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75235 9046, USA
    J Biol Chem 272:15959-66. 1997
    ..The synthesis of an active steroid hormone by back conversion of an inactive metabolite represents a potentially important mechanism by which the steady state level of a transcriptional effector can be regulated...
  101. pmc Association between SNPs within candidate genes and compounds related to boar taint and reproduction
    Maren Moe
    The Norwegian Pig Breeders Association NORSVIN, Hamar, Norway
    BMC Genet 10:32. 2009
    ..The aim of this study was to detect SNPs in boar taint candidate genes and to perform association studies for both single SNPs and haplotypes with levels of boar taint compounds and phenotypes related to reproduction...

Research Grants51

  1. Androgen Receptor Pathway and Risk of Hepatic Fibrosis in Hepatitis C
    DONNA LORRAINE WHITE; Fiscal Year: 2013
    ....
  2. Genetics and the Environment Associated with Male Reproduction (GEAR)
    Sheela Sathyanarayana; Fiscal Year: 2012
    ....
  3. MOLECULAR EPIDEMIOLOGY OF BIRTH DEFECTS
    Jeanne Manson; Fiscal Year: 2001
    ..The research proposal is an extension of the training component and exemplifies how molecular, genetic and epidemiologic approaches can be combined to study the etiology of birth defects. ..
  4. Estrogen Metabolism and Action in Prostate Cancer Etiology in PCPT
    Ashraful Hoque; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  5. Pharmacogenetics of Alcohol: Treatment Implications
    Jonathan Covault; Fiscal Year: 2009
    ....
  6. Prostate Cancer in Senegalese Men
    Serigne Gueye; Fiscal Year: 2005
    ..An understanding of the complex interplay of genetic variability at multiple loci and of environmental agents may improve our understanding of ethnic differences in prostate cancer etiology and risk prediction. ..
  7. 5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK
    Laurence Kedes; Fiscal Year: 2003
    ....
  8. 5 ALPHA-REDUCTASE IN THE PRIMATE EPIDIDYMIS
    MARY MAHONY; Fiscal Year: 1999
    ..The proposed hypothesis is: activin and inhibin, by opposing actions and in concert with androgens, modulate 5alpha-reductase gene expression in the primate proximal caput epididymis with minimal effect on the more distal corpus region. ..
  9. EFFECT OF MAMMARY TUMORS ON STEROID METABOLISM
    YUSUF ABUL HAJJ; Fiscal Year: 1980
    ..The effect of surgical removal of tumor and cell-free tumor extract administration will be studied in order to determine whether the tumor contains a factor(s) responsible for altered steroid metabolism...
  10. ENDOCRINE ROLES OF STEROID 5 ALPHA REDUCTASE ISOZYMES
    David Russell; Fiscal Year: 2003
    ....
  11. Androgen Pathway and Genetic Risk of Prostate Cancer
    Noel Weiss; Fiscal Year: 2002
    ..The identification and confirmation of high-risk genetic profiles for prostate cancer could enable better screening and potential preventive interventions aimed at the gene products. ..
  12. DETERMINANTS OF STEROID HORMONES IN BLACK AND WHITE MEN
    Susan Gapstur; Fiscal Year: 2006
    ....
  13. Breast cancer and HRT: genetic susceptibility within th*
    Kathleen Malone; Fiscal Year: 2006
    ..abstract_text> ..
  14. GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTS
    Brian Henderson; Fiscal Year: 2000
    ..g., hormone replacement therapy) that affect the risk of these three cancers. In addition to case control comparisons, the design allows for comparison of the frequency of these genetic polymorphisms across ethnic groups. ..
  15. Northeast Under/Grad Research Organization for Neuroscience
    Cheryl Frye; Fiscal Year: 2008
    ..Both of these outcomes are congruous with the Public Health Service's mission to ensure that there is a resource of well-trained scientists and health-care providers in the United States. [unreadable] [unreadable] [unreadable]..
  16. Minimally Invasive Surgical Therapies Treatment Consort*
    Claus Roehrborn; Fiscal Year: 2005
    ..The MIST Study Group will be a blueprint for a technology assessment group applicable to other areas of urology and other medical or surgical subspecialties. ..
  17. Interstitial Cystitis Clinical Research Network (ICCRN)
    J Nickel; Fiscal Year: 2007
    ..site with Dr. Nickel as PI has the experience, expertise and the proven ability to design, implement and enroll patients with IC in clinical strudies and will be a valuable partner in the proposed ICCRN and UCPPSCG. ..
  18. The Efficacy of TUMT and Neoadjuvant Finasteride for BPH
    Kevin McVary; Fiscal Year: 2005
    ..We are proposing a 3-arm, placebo/sham controlled, randomized clinical trial using changes in symptoms as the primary ..
  19. TUMT verses Medical Therapy in Treatment of BPH
    E Crawford; Fiscal Year: 2005
    ..The PI has enlisted the support of consultants who will assist in this important evaluation. The results of this analysis will be critical in allocating health care resources. ..
  20. Chronic Prostatitis Collaborative Research Network CPCRN
    J Nickel; Fiscal Year: 2007
    ..Nickel as PI has the experience, expertise and the proven ability to design, implement and enroll patients with CPPS in clinical studies and will be a valuable partner in the proposed CPCRN and UCPPSCG. ..
  21. MOLECULAR BASIS OF SEX STEROID ACTION IN PROSTATE CANCER
    Yuan Shan Zhu; Fiscal Year: 2005
    ..abstract_text> ..
  22. REGULATION OF PROSTATE GROWTH BY NEURAL FACTORS
    Kevin McVary; Fiscal Year: 2001
    ..Using this model allows one to explore the limits of understanding prostatic neuroregulation, to explore neurotrophic influences on exocrine gland development, and to possibly uncover novel methods to influence prostate disease. ..
  23. N O S AND NEUROPATHIC AND ENDOTHELIAL INDUCED ED
    Kevin McVary; Fiscal Year: 2002
    ..Results of this research will aid in the understanding of how diabetic neuropathy contributes to sexual dysfunction and elucidate possible mechanisms to prevent them. ..
  24. CHARACTERIZATION & TREATMENT OF CATEGORY III PROSTATITIS
    J Nickel; Fiscal Year: 2003
    ..Results from this 3 part study will be analyzed and correlated between groups and within groups, both concurrently and sequentially. ..
  25. ALCOHOL, GABA AND HORMONES: PHYSIOLOGY OF SUBUNIT CHANGE
    Sheryl S Smith; Fiscal Year: 2010
    ..The results from these studies may provide insight into potential mechanisms for effects of low dose ethanol at GABAR. ..
  26. Post-translational regulation of CYP17 activity
    Denis Magoffin; Fiscal Year: 2008
    ..We expect to utilize the molecular model to design new Pharmaceuticals to treat not only ovarian hyperandrogenism, but also other diseases of androgen excess such as prostate cancer and cardiovascular diseases. ..
  27. Modifiers of Cancer Risk in BRCA 1/2 Mutation Carriers
    Timothy Rebbeck; Fiscal Year: 2008
    ..Our substantial multidisciplinary experience will therefore allow us to readily translate basic science and epidemiological data to clinically relevant information. ..
  28. Prophytactic surgery in carriers of BRCA 1/2 mutations
    Timothy R Rebbeck; Fiscal Year: 2010
    ..These studies will motivate future studies of BRCA1/2-associated breast tumor biology, prevention, and treatment. ..
  29. Vascular and Inflammatory Predictors of MCI Risk and Progression
    ROSEBUD ROBERTS; Fiscal Year: 2008
    ..The K01 award will culminate in an R01 application that will pave the way for the candidate to become an independent investigator in MCI and AD research. [unreadable] [unreadable] [unreadable]..
  30. Oral Androgen Administration and Function in Man
    JOHN AMORY; Fiscal Year: 2008
    ..Matsumoto M.D., Director, Clinical Research Unit VA-Puget Sound and Professor of Medicine, University of Washington School of Medicine will co-mentor this award. [unreadable] [unreadable]..
  31. The Effects of Neuroactive Steroids on Acute Ethanol Withdrawal in Mice
    KATHERINE GILILLAND; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  32. Ethnic difference in prostate cancer
    Timothy R Rebbeck; Fiscal Year: 2010
    ....
  33. Steroids and GABA: Physiology of Receptor Subunit Change
    Sheryl S Smith; Fiscal Year: 2010
    ..These results may be relevant for alterations in mood, cognition and seizure susceptibility (i.e., catamenial epilepsy) reported during puberty and across the menstrual cycle. ..
  34. A Pooled Analysis to Identify New Ovarian Cancer Risk Factors
    Celeste Leigh Pearce; Fiscal Year: 2010
    ..Gaining a better understanding of ovarian cancer, which this project will provide, is critical to identifying women at risk and for improving the outcome for women who are diagnosed with this disease. ..
  35. GROWTH FACTOR CONTROL OF OVARIAN ANDROGEN BIOSYNTHESIS
    Denis Magoffin; Fiscal Year: 2001
    ..It is hoped that this will provide novel opportunities for developing new treatments for hyperandrogenism. ..
  36. MBD2 as a Target for Cancer Prevention and Treatment
    William Nelson; Fiscal Year: 2007
    ..abstract_text> ..
  37. Neuroactive Steroid Therapy of Catamenial Epilepsy
    DOODIPALA REDDY; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  38. Trainee-Focusted Training for Research Integrity
    Steven Jacobsen; Fiscal Year: 2003
    ..6. Identify high frequency perceptions or frames of reference, which are substantially at odds with accepted research norms and begin designing better interventions to alter them. ..
  39. Genetic Polymorphisms Benign Prostatic Hyperplasia
    ROSEBUD ROBERTS; Fiscal Year: 2004
    ..This community-based cohort study should provide insights that should improve our understanding of the genetic control of hormonal mechanisms in the pathogenesis of BPH. ..
  40. Fusion Proteins As Probes of P450 Structure and Function
    Richard Auchus; Fiscal Year: 2004
    ..In addition, this approach might be generally applicable to structural studies of membrane-bound proteins. ..
  41. Molecular Dissection of Benign Prostatic Hyperplasia
    Mark Rubin; Fiscal Year: 2004
    ..b) Validation of tissue markers using MTOPS samples. Aim 4: Validation of candidate serum biomarkers of symptomatic BPH. a) Serum Microarray Validation using Michigan samples. b) Validation of serum markers using MTOPS samples. ..
  42. Nutritional Biochemistry of beta-Carotene Dioxygenase
    A Andersson; Fiscal Year: 2005
    ..The studies described in this proposal will further our knowledge on vitamin A synthesis from dietary provitamin A carotenoids in man. ..
  43. The Progesterone Receptor Gene and Ovarian Cancer Risk
    CELESTE PEARCE; Fiscal Year: 2005
    ..We will also test our previous two case-control studies for any additional identified SNPs, including 326 cases and 493 controls (many of the SNPs have already been tested in these populations). ..
  44. AUA/SBUR Res. Conf.-"Inflammation in Prostate Diseases"
    William Nelson; Fiscal Year: 2005
    ..Support for this meeting will encourage the future development of urology research by providing mentoring for new investigators as well as education on this emerging research area. ..
  45. ANDROGEN PRODUCTION IN ADRENARCHE AND PCOS
    WALTER MILLER; Fiscal Year: 2006
    ..abstract_text> ..
  46. Insulin signaling in theca cells from polycystic ovaries
    Denis Magoffin; Fiscal Year: 2006
    ..The results of these studies are expected to yield specific molecular targets for novel therapies to treat women with PCOS. ..
  47. Urodynamic and Multiethnic Variability of Men Treated b*
    Steven Kaplan; Fiscal Year: 2005
    ..Baseline urodynamic parameters which may predict improved outcome after MIST 3. The success of various types of MIST in treating BPH in African - American, Hispanic and Caucasian men. ..
  48. Ovarian Cancer and Gonadotropin Signaling
    CELESTE PEARCE; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  49. ETIOLOGIC HETEROGENEITY IN LATE ONSET BREAST CANCER
    Timothy Rebbeck; Fiscal Year: 2001
    ..The results of these analyses will be used to attempt to elucidate the complex, multifactorial aetiology of late onset breast cancer. ..